Lead Drug Candidate: TNAX101A

Profile of TNAX101A

  1. Humanized murine anti-human DNAM-1 (CD226) monoclonal antibody
  2. Directly deactivates effector T cells
  3. Potentiates effector T cell suppressive effect of regulatory T cells
  4. Shows potent anti-inflammatory effects and anti-fibrotic effects
  5. Engineered to abolish Fc effector function

Expected Indications of TNAX101A

  1. Idiopathic Pulmonary Fibrosis (IPF)
  2. Inflammatory Bowel Disease (IBD)
  3. Renal Fibrosis
  4. Rheumatoid Arthritis (RA)

Development Stage of TNAX101A: Pre-clinical (Scheduled to be advanced intoFIH Study in 2022)